Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederbusinesswire.com
Business Wire - News by Company: Merck
Get the latest updates from Business Wire - News by Company: Merck directly as they happen.
Follow now 51 followers
Latest posts
Last updated 2 days ago
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
2 days ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of...
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
3 days ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2025 Global...
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
11 days ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of...
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
13 days ago
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of...
Merck Announces First-Quarter 2025 Financial Results
16 days ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Financial Results
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
about 1 month ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call...
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
about 1 month ago
RAHWAY, N.J.--(BUSINESS WIRE)--WINREVAIR reduced the risk of a composite of all-cause death...
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
about 1 month ago
RAHWAY, N.J.--(BUSINESS WIRE)-- #MRK--Merck (NYSE: MRK), known as MSD outside of the...
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
about 1 month ago
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission (EC) Approves Merck’s CAPVAXIVE® for Prevention...
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
about 2 months ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United...
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
about 2 months ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to...
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
about 2 months ago
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Data from Phase 3 Trials that...